PIRS - Pieris Pharmaceuticals Inc Stock Price, Fair Value and News

$12.00-1.00 (-7.69%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PIRS Price Action

Last 7 days

-16.7%

Last 30 days

-15.5%

Last 90 days

-18.4%

Trailing 12 Months

6.3%

PIRS RSI Chart

PIRS Valuation

Market Cap

15.8M

Price/Earnings (Trailing)

-0.99

Price/Sales (Trailing)

0.5

EV/EBITDA

-0.04

Price/Free Cashflow

-0.57

PIRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PIRS Fundamentals

PIRS Revenue

Revenue (TTM)

42.9M

PIRS Earnings

Earnings (TTM)

-16.0M

Earnings Growth (Yr)

73.15%

Earnings Growth (Qtr)

19.58%

PIRS Profitability

EBT Margin

-106.71%

Return on Equity

-98.06%

Return on Assets

-77.74%

Free Cashflow Yield

-176.65%

PIRS Investor Care

Shares Dilution (1Y)

6.85%

Diluted EPS (TTM)

-10.03

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	16.7M	33.3M	47.5M	42.9M
2022	27.0M	27.1M	28.5M	25.9M
2021	31.7M	23.7M	24.9M	31.4M
2020	51.0M	56.9M	44.7M	29.3M
2019	33.5M	27.1M	33.9M	46.3M
2018	28.1M	37.9M	42.3M	29.1M
2017	5.9M	6.7M	9.8M	25.3M
2016	4.0M	4.9M	5.2M	5.8M
2015	4.2M	3.7M	4.1M	2.9M
2014	10.7M	8.9M	7.1M	5.4M
2013	0	0	11.9M	12.4M
2012	0	0	0	11.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

CEO	Mr. Stephen S. Yoder J.D.
WEBSITE	pieris.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	127

Pieris Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Pieris Pharmaceuticals Inc? What does PIRS stand for in stocks?

PIRS is the stock ticker symbol of Pieris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pieris Pharmaceuticals Inc (PIRS)?

As of Thu Dec 19 2024, market cap of Pieris Pharmaceuticals Inc is 15.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PIRS stock?

You can check PIRS's fair value in chart for subscribers.

Is Pieris Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PIRS is over valued or under valued. Whether Pieris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Pieris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PIRS.

What is Pieris Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, PIRS's PE ratio (Price to Earnings) is -0.99 and Price to Sales (PS) ratio is 0.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PIRS PE ratio will change depending on the future growth rate expectations of investors.